scholarly journals Real-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1-3 positive lymph nodes: a retrospective study

2013 ◽  
Vol 55 (1) ◽  
pp. 121-128 ◽  
Author(s):  
I. Chitapanarux ◽  
E. Tharavichitkul ◽  
S. Jakrabhandu ◽  
P. Klunklin ◽  
W. Onchan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Real World ◽  
Breast Cancer Patients ◽  
Postmastectomy Radiotherapy ◽  
Positive Lymph Nodes

Postmastectomy Radiotherapy in T1–2 Female Breast Cancer Patients with 1–3 Positive Axillary Lymph Nodes: A Propensity Score Matched SEER Analysis

2021 ◽  
Author(s):  
Gang Xu ◽  
Shanshan Bu ◽  
Xiushen Wang ◽  
Hong Ge
Keyword(s):  
Breast Cancer ◽  
Propensity Score ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Female Breast Cancer ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Postmastectomy Radiotherapy ◽  
Female Breast ◽  
Positive Lymph Nodes

Abstract Purpose The application of postmastectomy radiotherapy (PMRT) in T1–2 female breast cancer patients with 1–3 positive lymph nodes has been controversial. We sought to determine the survival benefits of PMRT in the patients with T1–2 and 1–3 positive nodes. Methods A retrospective study using the Surveillance, Epidemiology, and End Results (SEER) Regs Custom Data (with additional treatment fields) from 2001 to 2011 was performed. Patients who received PMRT were matched by the propensity score with patients who did not receive PMRT. The Overall survival (OS) and breast cancer-specific survival (BCSS) were analyzed. Results We identified 56,725 female breast cancer patients with T1–2 and 1–3 positive nodes, and 18,646 patients were included in the analysis. After propensity score matching (1:1), with a median follow-up of 116 months, PMRT showed an increase in the OS (P = 0.018) but had no effect on the BCSS. The 10-year OS rates were 76.8% and 74.4%, and the 10-year BCSS rates were 82.8% and 82.2% for the patients who received and who did not receive PMRT, respectively. Only patients with 3 positive nodes could gain the benefit of PMRT for BCSS. Conclusion PMRT for patients with T1–2 and 1–3 positive lymph nodes could increase the 10-year OS, and had no effect on the 10-year BCSS. Subgroup analysis indicated that only patients with 3 positive lymph nodes could benefit from PMRT for both the OS and BCSS.

Postmastectomy Radiotherapy in T1–2 Women Breast Cancer Patients with 1–3 Positive Axillary Lymph Nodes: A Propensity Score Matched SEER Analysis

2020 ◽  
Author(s):  
Gang Xu ◽  
Shanshan Bu ◽  
Xiushen Wang ◽  
Hong Ge
Keyword(s):  
Breast Cancer ◽  
Propensity Score ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Cancer Specific Survival ◽  
Postmastectomy Radiotherapy ◽  
Positive Lymph Nodes

Abstract Purpose: The application of postmastectomy radiotherapy (PMRT) in T1–2 women breast cancer patients with 1–3 positive lymph nodes has been controversial. We sought to determine the survival benefits of PMRT in the patients with T1–2 and 1–3 positive nodes.Methods: A retrospective study using the Surveillance, Epidemiology, and End Results (SEER) Regs Custom Data (with additional treatment fields) from 2001 to 2011 was performed. Patients who received PMRT were matched by the propensity score with patients who did not receive PMRT. The Overall survival (OS) and breast cancer-specific survival (BCSS) were analyzed. Results: We identified 56,725 women breast cancer patients with T1–2 and 1–3 positive nodes, and 18,646 patients were included in the analysis. After propensity score matching (1:1), with a median follow-up of 116 months, PMRT showed an increase in the OS (P = 0.018) but had no effect on the BCSS. The 10-year OS rates were 76.8% and 74.4%, and the 10-year BCSS rates were 82.8% and 82.2% for the patients who received and who did not receive PMRT, respectively. Only patients with 3 positive nodes could gain the benefit of PMRT for BCSS.Conclusion: PMRT for patients with T1–2 and 1–3 positive lymph nodes could increase the 10-year OS, and had no effect on the 10-year BCSS. Subgroup analysis indicated that only patients with 3 positive lymph nodes could benefit from PMRT for both the OS and BCSS.

scholarly journals 75P Does postmastectomy radiotherapy benefit breast cancer patients with 1-3 positive lymph nodes?

2015 ◽  
Vol 26 ◽  
pp. ix16
Author(s):  
T. Koo ◽  
E.Y. Kang ◽  
J.H. Kim ◽  
S.Y. Park ◽  
S.W. Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Postmastectomy Radiotherapy ◽  
Positive Lymph Nodes

scholarly journals Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy

2018 ◽  
Vol 25 (7) ◽  
pp. 1912-1920 ◽  
Author(s):  
Shirin Muhsen ◽  
Tracy-Ann Moo ◽  
Sujata Patil ◽  
Michelle Stempel ◽  
Simon Powell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Postmastectomy Radiotherapy ◽  
Positive Lymph Nodes

Use of Postmastectomy Radiotherapy and Survival Rates for Breast Cancer Patients with T1–T2 and One to Three Positive Lymph Nodes

2015 ◽  
Vol 22 (13) ◽  
pp. 4295-4304 ◽  
Author(s):  
Dezheng Huo ◽  
Ningqi Hou ◽  
Nora Jaskowiak ◽  
David J. Winchester ◽  
David P. Winchester ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Survival Rates ◽  
Breast Cancer Patients ◽  
Postmastectomy Radiotherapy ◽  
Positive Lymph Nodes

scholarly journals Neoadjuvant chemotherapy or surgery: which is the optimal initial option for T3 breast cancer (> 5 cm)——a real world research from Chinese society of clinical oncology breast cancer database

2020 ◽  
Author(s):  
Haibo Wang ◽  
Jianbin Li ◽  
Meng Lv ◽  
Yan Mao ◽  
Gang Nie ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Real World ◽  
Maximum Diameter ◽  
Chinese Society ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Positive Lymph Nodes

Abstract Background: The objectives were to explore the real world treatment of T3 breast cancer (maximum diameter of tumor bigger than 5 centimeters). Materials and Methods: We selected T3 breast cases diagnosed from 2011 to 2017 in the CSCO BC database. These cases were categorized into two groups: non-NAC group and NAC group. Adjusted hazard ratios for known predictors of event free survival (EFS) using Kaplan-Meier and Cox proportional hazards regression. Results: The study included 868 patients: 49.0%(425/868) of patients chose NAC after diagnosis, 51.0%(443/868) chose surgery as their initial therapeutic strategy(non-NAC group). Compared with non-NAC group, patients in NAC group were correlated with clinical positive lymph nodes, hormonal receptor(HR) negative and human epidermal receptor growth factor 2(HER2) positive. For non-NAC group, only 87.1%(386/443) of patients were pathologic T3 after surgery, the overestimation of clinical examination of tumor lesion was 12.9%(57/443). In addition, there was no significance of EFS between the NAC group and non-NAC group(HR=0.82, 95%CI: 0.64-1.05). However, for T3 breast cancer patients with positive lymph nodes, HR negative and HER2 positive tumors, the NAC group had a better survival than the non-NAC group. Cox proportional analysis showed that lymph node negative, HER2 negative status and neoadjuvant chemotherapy were associated with a longer survival time. Conclusion: As the initial option for T3 breast cancer patients with positive lymph nodes, HR negative and HER2 positive tumors, neoadjuvant chemotherapy is the first therapy.

scholarly journals Postmastectomy radiotherapy and locoregional recurrence rate in high-risk breast cancer patients

2004 ◽  
Vol 12 (1) ◽  
pp. 39-43
Author(s):  
Danijela Scepanovic ◽  
Nada Bajic ◽  
Jovan Babic
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Locoregional Recurrence ◽  
Disease Free Survival ◽  
Postmenopausal Breast Cancer ◽  
Breast Cancer Patients ◽  
Postmastectomy Radiotherapy ◽  
Positive Lymph Nodes

BACKGROUND: Postmastectomy radiotherapy has been the topic for many debates over several years about its role on locoregional control as well as overall survival in premenopausal and postmenopausal breast cancer patients. METHODS: From 1994 till 1999, 233 patients underwent modified radical mastectomy for breast cancer. Among them there was 92 premenopausal patients (median age was 44 years) and 141 postmenopausal patients (median age was 60 years). Traditional prognostic factors were used to assess risk of locoregional recurrence: 84 patients were node-negative, 71 patients had 1 to 3 lymph nodes positive, and 71 patients had 4 and more positive lymph nodes; 103 patients had tumor less than 3 cm diameter and 130 patients had tumors grater than 3 cm. According to this, postmastectomy radio- therapy was applied in 125 patients of whom 117 patients (94%) had also adjuvant systemic therapy (chemotherapy and/or hormonal therapy). RESULTS: The locoregional recurrence was observed in 42 patients while 191 patients were free of (median follow-up time was 49 months). Locoregional recurrence developed in 10 patients who had postmastectomy radiotherapy and in 32 patients who did not had postmastectomy radiotherapy (p=0.0001). In the group of patients with locoregional recurrence event 5-year overall survival was 28% while 70% in the group of patients free of (p=0.00001). There was statistically significant advantage for post- mastectomy radiotherapy in the group of patients with 1 to 3 positive lymph nodes as well as for 4 and more positive lymph nodes group (p=0.0008). In addition there was statistically significant difference among postmastectomy radiotherapy group and no postmastectomy radiotherapy group for disease free survival (74% vs. 50%, 5-year disease free survival, p=0.0001) and overall survival (71% vs. 53%, 5-year overall survival, p=0.0422). CONCLUSION: Postmastectomy radiotherapy reduces locoregional recurrence rate and improves overall survival in premenopausal and postmenopausal breast cancer patients with tumors grater than 3cm diameter and positive axillary lymph nodes.

Sign in / Sign up

Export Citation Format

Share Document